Voltar
Artigo Acesso aberto Revisado por pares
BIBTEX RIS

The Beneficial Effect of the COVID-19 Vaccine Booster Dose among Healthcare Workers in an Infectious Diseases Center

2022; Multidisciplinary Digital Publishing Institute; Volume: 10; Issue: 4 Linguagem: Inglês

10.3390/vaccines10040552

ISSN

2076-393X

Autores

Agata Skrzat‐Klapaczyńska, Carlo Bieńkowski, Justyna D. Kowalska, Marcin Paciorek, Joanna Puła, Dominika Krogulec, Jarosław Stengiel, Agnieszka Pawełczyk, Karol Perlejewski, Sylwia Osuch, Marek Radkowski, Andrzej Horban,

Tópico(s)

Infection Control and Ventilation

Resumo

Introduction: Healthcare workers in Poland received a booster dose of the BNT162b2 mRNA vaccine (Pfizer-BioNTech, Manufacturer: Pfizer, Inc., and BioNTech; Moguncja, Germany) at the beginning of October 2021. Here, we report on the preliminary results of an ongoing clinical study into the antibody response to SARS-CoV-2 of healthcare workers previously exposed to the virus, with or without evidence of past infection, in the Hospital for Infectious Diseases in Warsaw before and after the vaccine booster dose. Methods: Blood samples were collected on the day the vaccine booster dose was administered and again 14 days later. The levels of SARS-CoV-2 IgG antibodies (against the n-protein, indicative of disease) and S-RBD (indicative of a response to vaccination) were measured. Results: One hundred and ten health care workers from the Hospital for Infectious Diseases were included in the study. The percentage of subjects with a positive test for anti-n-protein IgG antibodies at both time points remained unchanged (16, 14%), while a statistically significant increase in the percentage of subjects producing high levels of S-RBD antibodies (i.e., >433 BAU/mL) was observed (from 23, 21% to 109, 99%; p = 0.00001). Conclusions: The results of the study indicate that the booster dose of the vaccine significantly increases the percentage of people with high levels of S-RBD antibodies, regardless of previous contact with the virus, which may indicate greater protection against both the disease and a severe course of COVID-19.

Referência(s)